Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS-XII: 6 vs 12 Months Hormone Therapy with Radiotherapy for Prostate Cancer
NCT06855589Phase 3Not yet recruiting
- Sponsor
- Hôpital Charles-LeMoyne
- Start
- Mar 2025
- Primary completion
- Mar 2033
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in Prostate Adenocarcinoma (PRAD) (2 arms), sponsored by Hôpital Charles-LeMoyne. Primary endpoint: Biochemical Progression-Free Survival at 5 years. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
leuprolide
03
Conditions
Prostate Adenocarcinoma (PRAD)
Beyond the preview
Go deeper on NCT06855589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855589.